Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

By D. Jackman, William Pao, Gregory Riely, J. Engelman, M. Kris, P. Jänne, T. Lynch, B. Johnson, Vincent A. Miller. Journal of Clinical Oncology, 2010

798 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/10fca803e8f49b03a63f8e1da2b9d297d9f74fab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Jin-Yuan Shih
2. Shang-Gin Wu
3. William Pao
4. M. Hellmann
5. J. Chmielecki
6. A. Schoenfeld

In Pulmonary and Respiratory Medicine

1. Jin-Yuan Shih
2. Shang-Gin Wu
3. J. Chmielecki
4. William Pao

Citations in the corpus

• Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer (2018, positive): “In 2010, Jackman et al. proposed clinical criteria for acquired resistance to EGFR TKI based on the Response Evaluation Criteria in Solid Tumors (RECIST) [21, 22].”
• Acquired Resistance to Immune Checkpoint Inhibitors (2020, background): “Among other considerations, the EGFR criteria stipulated patients should have 1) documented initial objective response (partial or complete response by RECIST or WHO) to therapy OR significant and durable (> 6 months) clinical benefit (stable disease defined by RECIST or WHO) and 2) systemic progres”
• AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. (2015, neutral): “Any grade 3 (14) 10 (17) 16 (18) 19 (30) 7 (33) 55 (22)”
• Rociletinib in EGFR-mutated non-small-cell lung cancer. (2015, neutral): “Decreased appetite 19 (15) 1 (3) 6 (32) 4 (24) 3 (19) 3 (9) 2 (33) 18 (20)”
• Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer (2010, background): “To minimize reporting of false-positive and false-negative activity in clinical trials and to facilitate the identification of agents that truly overcome acquired resistance to gefitinib and erlotinib, the following clinical and molecular criteria were recently proposed to more precisely define acqu”
• AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer (2014, positive): “Out of the two confirmed partial responses described in this article, in addition to both patients’ tumors harboring the T790M mutations (according to local tests), one patient’s disease fits strict Jackman criteria for acquired resistance (50), receiving the drug directly after prolonged response a”